SANDOZ LTD
Sandoz, a division of the Novartis
group, is a world leader in high quality generics and
biopharmaceutical medicinal products. Sandoz develops and
markets a wide variety of active ingredients and finished
products, having a portfolio of more than 840 compounds in
over 5000 forms. Novartis is the only major pharmaceutical
company to have leadership positions in both patented
prescription drugs and generic pharmaceuticals.
In 2005, Hexal AG (Germany) and EonLabs Inc. (US)
became part of Sandoz. In 2006, the business employed
about 21 000 people worldwide. It sold its products in more
than 110 countries and posted sales of US$6 billion.
Sandoz's recombinant human GH Omnitrope® received
marketing authorisation from the European Commission in
April 2006 and has been launched subsequently in several
European countries. In the US, Omnitrope® was launched in January 2007. In Australia, Omnitrope® has been on the
market since November 2005.
Biosimilar medicines made by Sandoz:
- fully adhere to the new and rigorous European standards for biosimilar medicinal products
- guarantee a high quality production process, as Sandoz ranks among the world's largest and most experienced manufacturers of biotechnological products
- ensure patient care and safety through appropriate
preclinical development, clinical trials and postmarketing
surveillance, including a state of the art
pharmacovigilance system
- help reduce the burden on healthcare systems by
providing the public with safe and effective medicines at
competitive prices.
Sandoz International GmbH, Industriestrasse 25,
83607 Holzkirchen, Germany
Tel: +49-8024-4762591
Fax: +49-8024-4762599
http://www.sandoz.com